Side-by-side · Research reference
DihexavsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BHuman-MechanisticAUTO-DRAFTED12/39 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
Dihexa
Semax
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
—
—
Origin
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
Semax
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Clinical status
No Phase 1, 2, or 3 trials published
—
Frequency
—
2–3× per day during cognitive demand
Lower / starter dose
—
100 mcg / dose
Duration
—
10–14 day cycles, repeated PRN
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
—
Morning + early afternoon
Half-life
—
Short plasma; CNS effect lasts ~3–6 hr
04Side Effects & Safety
Parameter
Dihexa
Semax
Human safety data
None available — no human clinical trials
—
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Long-term safety
—
Limited Western RCT data
Pregnancy / OB
—
Avoid
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
Dihexa
Semax
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
—
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
—
Refrigerate after reconstitution; light-protected.
5. Caveat
—
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
Dihexa
— no documented stacks
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation